Payment overview · 2025
General Payments
$434.44
27 reported records · 4 companies
Healthcare provider profile · identity verified
Shabih U Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST CHESTER, PA · NPI 1578571063
Verified facts
What the public records show
CMS Open Payments records show Shabih U Khan, MD received $434.44 in general payments during 2025 across 27 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 86.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 442 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $376.71 | 86.7% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.43 | 6.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.24 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.06 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $434.44 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $376.71 | 23 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 442 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
442 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 739 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 73 |
| Gabapentin | Gabapentin | 452 | 38 |
| Eliquis | Apixaban | 442 | 39 |
| Furosemide | Furosemide | 391 | 26 |
| Metformin Hcl | Metformin Hcl | 347 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 23 |
| Lisinopril | Lisinopril | 261 | 36 |
| Potassium Chloride | Potassium Chloride | 261 | 24 |
| Carvedilol | Carvedilol | 260 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 32 |
| Icosapent Ethyl | Icosapent Ethyl | 229 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 52 |
| Lansoprazole | Lansoprazole | 191 | 18 |
| Losartan Potassium | Losartan Potassium | 190 | 43 |
| Trazodone Hcl | Trazodone Hcl | 186 | 20 |
| Donepezil Hcl | Donepezil Hcl | 182 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 22 |
| Buspirone Hcl | Buspirone Hcl | 173 | 19 |
| Omeprazole | Omeprazole | 173 | 35 |
| Levetiracetam | Levetiracetam | 159 | 12 |
| Famotidine | Famotidine | 155 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 20 |
| Prednisone | Prednisone | 134 | 36 |
| Memantine Hcl | Memantine Hcl | 133 | 13 |
| Sertraline Hcl | Sertraline Hcl | 113 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 11 |
| Montelukast Sodium | Montelukast Sodium | 109 | 17 |
| Methylprednisolone | Methylprednisolone | 106 | 74 |
| Farxiga | Dapagliflozin Propanediol | 105 | 16 |
| Aripiprazole | Aripiprazole | 96 | suppressed |
| Jardiance | Empagliflozin | 96 | suppressed |
| Atenolol | Atenolol | 95 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 91 | suppressed |
| Latanoprost | Latanoprost | 88 | 12 |
| Divalproex Sodium | Divalproex Sodium | 83 | suppressed |
| Ezetimibe | Ezetimibe | 83 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 83 | 24 |
| Lorazepam | Lorazepam | 80 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | suppressed |
| Primidone | Primidone | 75 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 73 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 69 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 12 |
| Spironolactone | Spironolactone | 69 | suppressed |
| Meloxicam | Meloxicam | 68 | 14 |
| Alprazolam | Alprazolam | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 63 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 12 |
| Bumetanide | Bumetanide | 58 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | suppressed |
| Simvastatin | Simvastatin | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 14 |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Mounjaro | Tirzepatide | 51 | 18 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Pregabalin | Pregabalin | 47 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 37 |
| Allopurinol | Allopurinol | 42 | 13 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Ozempic | Semaglutide | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Humalog | Insulin Lispro | 38 | suppressed |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Nystatin | Nystatin | 36 | 23 |
| Valsartan | Valsartan | 35 | 13 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Glucagon Emergency Kit | Glucagon | 33 | 14 |
| Hydrocortisone | Hydrocortisone | 33 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | 13 |
| Levofloxacin | Levofloxacin | 31 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Baclofen | Baclofen | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 12 |
| Finasteride | Finasteride | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 25 | suppressed |
| Hydroxyurea | Hydroxyurea | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 15 |
| Azithromycin | Azithromycin | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 21 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | 18 |
| Cephalexin | Cephalexin | 19 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 11 |
| Fluconazole | Fluconazole | 17 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $434.44 · 27 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ELIQUIS, Ozempic, QULIPTA, Rybelsus, UBRELVY, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error